Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
I-MAB ( (IMAB) ) just unveiled an update.
On August 20, 2025, I-Mab announced its financial results for the first half of 2025, highlighting significant progress in its clinical pipeline, particularly with the drug givastomig. The company presented promising Phase 1b data for givastomig in combination with immunochemotherapy, showing an 83% objective response rate in gastric cancer patients. Additionally, I-Mab strengthened its financial position with a $61.2 million underwritten offering, ensuring funding through 2028, and acquired upstream rights to givastomig’s parental antibody, enhancing its intellectual property portfolio.
The most recent analyst rating on (IMAB) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on I-MAB stock, see the IMAB Stock Forecast page.
Spark’s Take on IMAB Stock
According to Spark, TipRanks’ AI Analyst, IMAB is a Neutral.
The overall stock score of 45 reflects I-MAB’s substantial financial challenges, particularly in terms of profitability and cash flow generation, which heavily impact its financial performance. Despite a modest technical uptrend, valuation metrics point to significant risks, with ongoing losses and a negative P/E ratio limiting its appeal. The absence of recent earnings call data or notable corporate events further solidifies the overall cautious outlook.
To see Spark’s full report on IMAB stock, click here.
More about I-MAB
I-Mab is a U.S.-based global biotech company focused on developing precision immuno-oncology agents for cancer treatment.
Average Trading Volume: 1,918,881
Technical Sentiment Signal: Buy
Current Market Cap: $401.8M
Find detailed analytics on IMAB stock on TipRanks’ Stock Analysis page.